world
3 known investors
Sidewinder Bio develops next-generation bispecific antibody-drug conjugates (ADCs) designed to treat solid tumors with enhanced specificity for difficult-to-treat cancers. The company engineers therapies targeting receptor co-complexes to improve therapeutic window and tumor cell specificity.